Table 2 Treatment regimens
Items | CCA patients (N = 40) |
|---|---|
Treatment line, n (%) | Â |
 First | 21 (52.5) |
 Second or above | 19 (47.5) |
ICI treatment, n (%) | 40 (100.0) |
ICI regimen, n (%) | Â |
 Camrelizumab | 19 (47.5) |
 Sintilimab | 9 (22.5) |
 Pembrolizumab | 7 (17.5) |
 Nivolumab | 3 (7.5) |
 Durvalumab | 2 (5.0) |
Combination treatment, n (%) | 40 (100.0) |
Combination treatment regimen, n (%) | Â |
 Capecitabine + oxaliplatin | 15 (37.5) |
 Lenvatinib | 10 (25.0) |
 Gemcitabine + cisplatin | 8 (20.0) |
 Gemcitabine + S-1 | 7 (17.5) |